ASH 2015: Clinical discussant in this ASH/FDA session, Professor Paul Richardson (Harvard medical School, Boston, USA), discusses the clinical relevance of the new oral proteazome inhibitor ixazomib and two new monoclonal antibodies daratumumab and elotuzumab approved in the last few weeks by the FDA
Experts try to provide clarity in dizzying myeloma landscape by Thomas R. Collins: There’s no doubt that the bonanza of new multiple myeloma therapies is a blessing to… read more.